Bioretec has been rebuilding its commercial foundation during 2025 and is seeking to restore damaged investor confidence. To finance its growth strategy, the company announced it is considering a 15 MEUR share issue. Bioretec's CEO Sarah Hubar-Fisher in an interview with analyst Antti Siltanen.
Topics:
00:00 Introduction
00:15 Bioretec’s year 2025
00:45 Main reasons for stalled growth
02:21 The commercial progress of RemeOs
03:26 Situation in China
04:30 Chances in go-to-market strategy
05:22 Most important things to achieve in the US this year
06:40 Outlook for broadening the portfolio and expanding indications
07:47 Situation in Europe
08:51 Finnish hospitals
09:28 Partnership possibilities
10:38 KPI reporting
12:59 Plans regarding funding
